GlassScriptPhysician profile
Johnson Thomas
NPI 1922231331
$51,451.58
in general payments reported to CMS, 2019-2025
21 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $9,802 · 2021: $18K · 2022: $18K · 2023: $5,357 · 2024: $47.91 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,808 · Food and Beverage: $846 · Education: $30.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,807.75 |
| Food and Beverage | $845.58 |
| Education | $30.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $49,915.78 | 2019-2023 | Rybelsus, Ozempic |
| Dexcom, INC. | $418.75 | 2021-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $382.02 | 2022-2023 | Tepezza |
| Amgen INC. | $135.61 | 2022 | |
| Medtronic, INC. | $126.10 | 2023-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $109.83 | 2019-2020 | |
| Abbott Laboratories | $93.31 | 2021-2025 | Freestyle Libre |
| Sequel Med Tech, LLC | $45.80 | 2025 | Twiist |
| Kyowa Kirin, INC. | $30.93 | 2025 | |
| Insulet Corporation | $29.56 | 2025 | Omnipod |
| Pfizer INC. | $29.32 | 2025 | |
| Recordati_rare_diseases_inc. | $27.91 | 2024 | Signifor Lar, Isturisa |
| Sanofi-Aventis U.S. LLC | $22.84 | 2023 | |
| Tandem Diabetes Care, INC. | $22.14 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $18.73 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $15.25 | 2025 | Senza |
| Allergan, INC. | $14.15 | 2019 | |
| Beta Bionics, INC. | $7.80 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Clarus Therapeutics INC. | $5.75 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnson Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.